Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENV-101 in Idiopathic Pulmonary Fibrosis (WHISTLE-PF)
NCT06422884Phase 2Active, not recruiting
- Sponsor
- Endeavor BioMedicines
- Start
- Nov 2024
- Primary completion
- Oct 2026
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of taladegib in idiopathic pulmonary fibrosis (IPF) and progressive fibrosing interstitial lung disease (PF-ILD) (4 arms), sponsored by Endeavor BioMedicines. Primary endpoint: percent predicted forced vital capacity at 24 weeks. Started Nov 2024; status: active, not recruiting.
02
Drugs
taladegib
03
Conditions
idiopathic pulmonary fibrosis (IPF)progressive fibrosing interstitial lung disease (PF-ILD)
Beyond the preview
Go deeper on NCT06422884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06422884.